Cantor Fitzgerald Reiterates “Overweight” Rating for Apellis Pharmaceuticals (NASDAQ:APLS)

Cantor Fitzgerald reaffirmed their overweight rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report report published on Thursday morning, Briefing.com Automated Import reports. They currently have a $50.00 price objective on the stock, down from their previous price objective of $52.00.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. upgraded shares of Apellis Pharmaceuticals from a neutral rating to an overweight rating and boosted their target price for the company from $35.00 to $49.00 in a report on Friday, July 12th. Oppenheimer assumed coverage on shares of Apellis Pharmaceuticals in a report on Tuesday, July 9th. They issued an outperform rating and a $52.00 target price on the stock. ValuEngine upgraded shares of Apellis Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, July 3rd. Cowen reiterated a buy rating and issued a $40.00 target price on shares of Apellis Pharmaceuticals in a report on Sunday, June 16th. Finally, Zacks Investment Research lowered shares of Apellis Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, July 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. Apellis Pharmaceuticals has an average rating of Buy and a consensus target price of $45.14.

APLS stock opened at $27.44 on Thursday. The stock has a market capitalization of $1.75 billion, a PE ratio of -11.73 and a beta of 0.75. Apellis Pharmaceuticals has a 52 week low of $11.45 and a 52 week high of $29.89. The stock’s 50-day moving average is $25.96. The company has a quick ratio of 15.23, a current ratio of 8.67 and a debt-to-equity ratio of 0.08.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.20). On average, equities research analysts expect that Apellis Pharmaceuticals will post -3.59 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Apellis Pharmaceuticals by 59.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,944 shares of the company’s stock worth $75,000 after acquiring an additional 1,099 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Apellis Pharmaceuticals during the 1st quarter worth approximately $112,000. BNP Paribas Arbitrage SA increased its position in shares of Apellis Pharmaceuticals by 250,533.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,519 shares of the company’s stock valued at $147,000 after purchasing an additional 7,516 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its position in shares of Apellis Pharmaceuticals by 356.7% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,216 shares of the company’s stock valued at $161,000 after purchasing an additional 9,541 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Apellis Pharmaceuticals by 146.0% in the 4th quarter. Bank of America Corp DE now owns 17,533 shares of the company’s stock valued at $231,000 after purchasing an additional 10,407 shares during the last quarter. Institutional investors own 63.48% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.

Featured Article: CBOE Russell 2000® Volatility Index

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.